In a separate patient, we confirmed enhancement of tumor killing by circulating and intratumoral CD4+ T cells by E-cadherin blockade that is specific for KLRG1, and also MHC class II in agreement with our prior findings (7), and was not impacted by isotype control antibodies (Supplemental Figure 7C). The gene discussed is CDH1; the disease is neoplasm.